Abnormal may leads to higher seizure relapse rate by EEG findings compared with normal EEG (low certainty).
It is very uncertain whether embryo culture with low oxygen concentration changes congenital abnormalities compared with embryo culture with atmospheric oxygen concentration (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether summary of findings table ‐ Metformin + levonorgestrel (intrauterine… changes abnormal uterine bleeding compared with levonorgestrel intrauterine system (very low certainty).
It is very uncertain whether summary of findings table ‐ Metformin changes abnormal uterine bleeding compared with megestrol (very low certainty).
Respiratory syncytial virus vaccine showed no clear difference in congenital abnormalities compared with placebo (high certainty).
Immediate antibiotics showed no clear difference in abnormal tympanometry at 4 weeks compared with expectant observation (moderate certainty).
Antibiotics leads to lower abnormal tympanometry ‐ 2 to 4 weeks compared with placebo (high certainty).
Antibiotics showed no clear difference in abnormal tympanometry ‐ 3 months compared with placebo (high certainty).
It is very uncertain whether nasal interfaces (single nasal prong, binasal prongs (long or… changes cranial ultrasound abnormalities (IVH grade ≥ 3 or cystic… compared with face mask (very low certainty).
Individual tailored showed no clear difference in death or abnormal neurodevelopmental outcome (various definitions) compared with continuous tapered dexamethasone regimen (low certainty).
It is very uncertain whether lower changes death or abnormal neurodevelopmental outcome (various definitions)… compared with higher cumulative dose dexamethasone regimen (very low certainty).
Later showed no clear difference in death or abnormal neurodevelopmental outcome (various definitions) compared with earlier initiation of dexamethasone therapy (low certainty).
It is very uncertain whether pulse changes death or abnormal neurodevelopmental outcome (various definitions) compared with continuous dexamethasone therapy (very low certainty).
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal ALT increase (42 days) compared with artesunate‐amodiaquine (AS‐AQ) (low certainty).
It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal AST increase (42 days) compared with artesunate‐amodiaquine (AS‐AQ) (very low certainty).
It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal bilirubin increase (42 days) compared with artesunate‐amodiaquine (AS‐AQ) (very low certainty).
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal ALT increase (42 days) compared with mefloquine plus artesunate (MQ + AS) (low certainty).
It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal AST increase (42 days) compared with mefloquine plus artesunate (MQ + AS) (very low certainty).
It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal bilirubin increase (42 days) compared with mefloquine plus artesunate (MQ + AS) (very low certainty).